A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

• Status: Recruiting
• Trial end date: 2021-06-15
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 2 open-label, dose-escalation study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 in patients with CF with at least one G542X allele.

In total, up to eight patients will be enrolled in the trial; up to 4 patients will be homozygotes to G542X, and the remaining patients will be compound heterozygotes with G542X and with any Class 1 or Class 2 mutation, excluding F508del.

Each patient will receive 4 escalating doses as follows:

• 0.3 mg/kg per day SC

• 0.75 mg/kg per day SC

• 1.5 mg/kg per day SC

• An individualized dose, as high as 3.0 mg/kg per day SC, based on the patients observed safety and tolerability, PK at previous doses and the results of laboratory tests.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eloxx Pharmaceuticals, Inc.
• Treatments: Cardiac Glycosides

Criteria

Inclusion Criteria:

1. Males and females age 18 years and above

2. A confirmed diagnosis of nmCF with a documented G542X mutation, homozygote, or compound heterozygote with one of the specified mutations. For heterozygotes, one mutation has to be G542X, and the second mutation has to be any Class 1 or Class 2 mutation excluding F508del. Patients with one G542X allele and a second allele that is not a Class 1 or Class 2 mutation may be potentially allowed but only after discussion on a case by case basis with and written approval from the Sponsor.

3. Documented SCC ≥60 mEq

4. FEV1 ≥40% predicted normal for age, gender and height at Screening (Knudson Equation)

5. Body mass index (BMI) of 19.0 to 30.0 kg/m2 (inclusive). Patients with a lower BMI may be entered into the study at the discretion of the investigator following consultation with the Sponsor.

Exclusion Criteria:

1. Participation in clinical study including administration of any investigational drug or device in the last 30 days or 5 half-lives (whichever is longer) prior to investigational product dosing in the current study

2. History of any organ transplantation

3. Major surgery within 180 days (6 months) of Screening

4. Patients without documented prior aminoglycoside exposure who have a mitochondrial mutation that has been shown to increase sensitivity to aminoglycosides

5. Known allergy to any aminoglycoside

6. Patients with any abnormality at ENT screening, that indicates the presence of a vestibular toxicity associated with prior exposure to aminoglycosides.

7. Dizziness Handicap Inventory (DHI)-H score at screening must be >16.

8. Patients receiving CFTR modulators within 2 months of study treatment